SOX2 and glioma: CRISPR-Cas9 technology was utilized to generate SOX2-KO cells from glioma cell lines (U251, LN229, and CCF) and primary GSCs, which exhibit relatively higher SOX2 expression and possess higher HCMV infection efficiency than the other three cell lines.